ARS Pharmaceuticals, Inc. Proceeds from Issuance of Debt
ARS Pharmaceuticals, Inc. (SPRY) reported Proceeds from Issuance of Debt of $96.26 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfDebt · last filed 2026-03-09
- ARS Pharmaceuticals, Inc. proceeds from issuance of debt for the quarter ending 2025-12-31 was -$1.49M.
- ARS Pharmaceuticals, Inc. proceeds from issuance of debt for the quarter ending 2024-12-31 was $0.00.
- ARS Pharmaceuticals, Inc. proceeds from issuance of debt for fiscal 2025 was $96.26M.
- ARS Pharmaceuticals, Inc. proceeds from issuance of debt for fiscal 2024 was $0.00.
| Period end | Proceeds from Issuance of Debt 3 month | Proceeds from Issuance of Debt 9 month | Proceeds from Issuance of Debt 12 month |
|---|---|---|---|
| 2025-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $96.26M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $97.75M 10-Q · filed 2025-11-10 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |